Arrhythmias & electrophysiology
High-risk Brugada syndrome: factors associated with arrhythmia recurrence and benefits of epicardial ablation in addition to implantable cardioverter defibrillator implantation
Authors' conclusion
Our study underscores the role of BrS substrate extent as a crucial prognostic factor for recurrent VF and validates the safety and efficacy of RFA when compared with a no-RFA group.
Study context
- Population
- Selected symptomatic Brugada syndrome patients with implantable cardioverter defibrillator (ICD)
- Participants
- 257 patients
- Exposure
- Epicardial radiofrequency ablation (RFA) plus ICD vs ICD only
- RFAn = 206
- no-RFAn = 51reference
- Outcome
- Risk factors for VF events pre-ablation and freedom from VF events post-ablation
Methodological detailslong-term registry
- Long-term registry
Main finding
As reported in the abstract
Patients with ventricular fibrillation (VF) episodes and VF storms, pre-RFA follow-up (median 27 months)
53
Independent risk factor for VF: substrate size, HR
1.13
95% CI 1.08–1.18P < 0.001
Independent risk factor for VF: aborted cardiac arrest, HR
2.98
95% CI 1.68–5.28P < 0.001
Independent risk factor for VF: SCN5A variants, HR
2.22
95% CI 1.15–4.27P = 0.017
Observational data: associations, not effects.
Safety
- No major procedure-related complications with RFA
Original publication
High-risk Brugada syndrome: factors associated with arrhythmia recurrence and benefits of epicardial ablation in addition to implantable cardioverter defibrillator implantation. Europace. Published 22 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →